Please use this identifier to cite or link to this item:

TitleCD147 and MCT1 - potential partners in bladder cancer aggressiveness and cisplatin resistance
Author(s)Afonso, Julieta Alexandra Pereira
Santos, Lúcio
Gonçalves, Vera M.
Morais, António
Amaro, T.
Longatto Filho, Adhemar
Baltazar, Fátima
Monocarboxylate transporters
Tumor microenvironment
Urothelial bladder cancer
Issue date2015
JournalMolecular carcinogenesis
CitationAfonso, J., Santos, L. L., Miranda-Gonçalves, V., Morais, A., Amaro, T., Longatto-Filho, A., & Baltazar, F. (2015). CD147 and MCT1-potential partners in bladder cancer aggressiveness and cisplatin resistance. Molecular Carcinogenesis, 54(11), 1451-1466. doi: 10.1002/mc.22222
Abstract(s)The relapsing and progressive nature of bladder tumors, and the heterogeneity in the response to cisplatin-containing regimens, are the major concerns in the care of urothelial bladder carcinoma (UBC) patients. The metabolic adaptations that alter the tumor microenvironment and thus contribute to chemoresistance have been poorly explored in UBC setting. We found significant associations between the immunoexpressions of the microenvironment-related molecules CD147, monocarboxylate transporters (MCTs) 1 and 4, CD44 and CAIX in tumor tissue sections from 114 UBC patients. The presence of MCT1 and/or MCT4 expressions was significantly associated with unfavorable clinicopathological parameters. The incidence of CD147 positive staining significantly increased with advancing stage, grade and type of lesion, and occurrence of lymphovascular invasion. Similar associations were observed when considering the concurrent expression of CD147 and MCT1. This expression profile lowered significantly the 5-year disease-free and overall survival rates. Moreover, when selecting patients who received platinum-based chemotherapy, the prognosis was significantly worse for those with MCT1 and CD147 positive tumors. CD147 specific silencing by small interfering RNAs (siRNAs) in UBC cells was accompanied by a decrease in MCT1 and MCT4 expressions and, importantly, an increase in chemosensitivity to cisplatin. Our results provide novel insights for the involvement of CD147 and MCTs in bladder cancer progression and resistance to cisplatin-based chemotherapy. We consider that the possible cooperative role of CD147 and MCT1 in determining cisplatin resistance should be further explored as a potential theranostics biomarker.
Description"Article first published online: 27 SEP 2014"
Publisher version
AccessOpen access
Appears in Collections:ICVS - Artigos em Revistas Internacionais com Referee

Files in This Item:
File Description SizeFormat 
afonso j_molec carc 2014 posp.pdf5,64 MBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID